Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups

International Journal of Hematology

Volumn 97, Issue 1, 2013, Pages 98-102

  Kihara, Rika ^a,b   Watanabe, Tomoyuki ^a,c   Yano, Takahiro ^a,d   Uike, Naokuni ^a,e   Okamura, Seiichi ^a   Kawano, Fumio ^a,f   Hanada, Shuichi ^a,g   Sunami, Kazutaka ^a   Inoue, Nobumasa ^a   Sawamura, Morio ^a   Yoshida, Shin Ichiro ^a,h   Shimomura, Takeshi ^a,i   Kitano, Kiyoshi ^a,j   Kojima, Yuki ^a,b   Horibe, Keizo ^a,b   Nagai, Hirokazu ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

ⁱ National Hospital Organization   (Japan)

^j National Hospital Organization Matsumoto Medical Center Matsumoto Hospital   (Japan)

more..

Author keywords

DLBCL; IPI; Mature T cell lymphoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; T CELL LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84872965680     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1243-2     Document Type: Article

References (7)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-18.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.
3. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan K, et al. Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402-8.
4. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-21. (Pubitemid 38029941)
5. Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008;111(9):4463-70.
6. Nagai H, Yano T, Watanabe T, Uike N, Okamura S, Hanada S, et al. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. Br J Haematol. 2008;143(5):672-80.
7. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Groupe d'Etudes des Lymphomes de l'Adulte (GELA), et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92(1):76-82. (Pubitemid 28303178)